{
    "hands_on_practices": [
        {
            "introduction": "The journey from a genetic variant to a clinical outcome begins at the molecular level. This exercise demonstrates how to quantify the functional consequence of a common *SLCO1B1* variant using data from in vitro experiments. By applying Michaelis–Menten kinetics, you will calculate the intrinsic uptake clearance ($CL_{\\text{int,uptake}}$), a key parameter that represents the transporter's efficiency and serves as the primary input for more complex pharmacokinetic models .",
            "id": "4572250",
            "problem": "A variant in Solute Carrier Organic Anion Transporter Family Member 1B1 (*SLCO1B1*), specifically the missense change valine to alanine at position $174$ (V174A; reference single nucleotide polymorphism identifier rs4149056), is known to alter hepatic uptake mediated by the encoded transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1). Consider in vitro uptake experiments conducted in transporter-expressing membrane preparations under conditions where uptake is well-described by saturable kinetics attributable to a single transporter system. Assume the uptake rate $v$ as a function of substrate concentration $[S]$ follows the Michaelis–Menten relationship, which is a well-tested description for carrier-mediated processes:\n$$\nv([S])=\\frac{V_{\\max}[S]}{K_{m}+[S]}.\n$$\nIn clinical pharmacology, the intrinsic uptake clearance, denoted $CL_{\\text{int,uptake}}$, is operationally defined as the initial slope of the uptake rate versus concentration relationship at low substrate concentrations (the linear, non-saturating limit), that is,\n$$\nCL_{\\text{int,uptake}}=\\lim_{[S]\\to 0}\\frac{v([S])}{[S]}.\n$$\nExperiments performed with wild-type *SLCO1B1* and the V174A variant yield the following parameter estimates: wild-type $V_{\\max,\\text{WT}}=120$ pmol/min/mg protein and $K_{m,\\text{WT}}=8$ $\\mu$M; variant $V_{\\max,\\text{V174A}}=70$ pmol/min/mg protein and $K_{m,\\text{V174A}}=8$ $\\mu$M. Using only the definitions and relationships provided above, compute the fold-change in intrinsic uptake clearance for the V174A variant relative to wild-type, defined as\n$$\n\\text{fold-change}=\\frac{CL_{\\text{int,uptake,V174A}}}{CL_{\\text{int,uptake,WT}}}.\n$$\nRound your final answer to three significant figures and report it as a decimal number without units.",
            "solution": "The problem requires the calculation of the fold-change in intrinsic uptake clearance for the V174A variant of the OATP1B1 transporter relative to the wild-type (`WT`). The problem is valid as it is scientifically grounded, well-posed, and provides all necessary information.\n\nFirst, we must derive a formal expression for the intrinsic uptake clearance, $CL_{\\text{int,uptake}}$, from the provided definitions. The uptake rate $v$ as a function of substrate concentration $[S]$ is given by the Michaelis–Menten equation:\n$$\nv([S]) = \\frac{V_{\\max}[S]}{K_{m}+[S]}\n$$\nThe intrinsic uptake clearance is defined as the initial slope of the uptake rate versus concentration relationship at low substrate concentrations:\n$$\nCL_{\\text{int,uptake}} = \\lim_{[S]\\to 0}\\frac{v([S])}{[S]}\n$$\nTo find an expression for $CL_{\\text{int,uptake}}$ in terms of the Michaelis-Menten parameters $V_{\\max}$ and $K_m$, we substitute the expression for $v([S])$ into the definition of $CL_{\\text{int,uptake}}$:\n$$\nCL_{\\text{int,uptake}} = \\lim_{[S]\\to 0} \\left( \\frac{1}{[S]} \\cdot \\frac{V_{\\max}[S]}{K_{m}+[S]} \\right)\n$$\nFor $[S] \\neq 0$, the expression inside the limit can be simplified by canceling the $[S]$ terms in the numerator and denominator:\n$$\nCL_{\\text{int,uptake}} = \\lim_{[S]\\to 0} \\frac{V_{\\max}}{K_{m}+[S]}\n$$\nEvaluating the limit as $[S]$ approaches $0$ yields:\n$$\nCL_{\\text{int,uptake}} = \\frac{V_{\\max}}{K_{m}+0} = \\frac{V_{\\max}}{K_{m}}\n$$\nThis establishes that the intrinsic uptake clearance is the ratio of the maximum uptake rate to the Michaelis constant.\n\nNext, we apply this relationship to both the wild-type (`WT`) and the V174A variant transporters using the provided parameter values.\n\nFor the wild-type transporter:\n$V_{\\max,\\text{WT}} = 120$ pmol/min/mg protein\n$K_{m,\\text{WT}} = 8$ $\\mu$M\nThe intrinsic uptake clearance for the wild-type is:\n$$\nCL_{\\text{int,uptake,WT}} = \\frac{V_{\\max,\\text{WT}}}{K_{m,\\text{WT}}} = \\frac{120}{8} \\, \\frac{\\text{pmol/min/mg protein}}{\\mu\\text{M}}\n$$\n\nFor the V174A variant transporter:\n$V_{\\max,\\text{V174A}} = 70$ pmol/min/mg protein\n$K_{m,\\text{V174A}} = 8$ $\\mu$M\nThe intrinsic uptake clearance for the variant is:\n$$\nCL_{\\text{int,uptake,V174A}} = \\frac{V_{\\max,\\text{V174A}}}{K_{m,\\text{V174A}}} = \\frac{70}{8} \\, \\frac{\\text{pmol/min/mg protein}}{\\mu\\text{M}}\n$$\n\nThe problem asks for the fold-change, which is defined as the ratio of the variant's clearance to the wild-type's clearance:\n$$\n\\text{fold-change} = \\frac{CL_{\\text{int,uptake,V174A}}}{CL_{\\text{int,uptake,WT}}}\n$$\nSubstituting the expressions for the clearances:\n$$\n\\text{fold-change} = \\frac{\\left(\\frac{V_{\\max,\\text{V174A}}}{K_{m,\\text{V174A}}}\\right)}{\\left(\\frac{V_{\\max,\\text{WT}}}{K_{m,\\text{WT}}}\\right)} = \\frac{V_{\\max,\\text{V174A}}}{V_{\\max,\\text{WT}}} \\cdot \\frac{K_{m,\\text{WT}}}{K_{m,\\text{V174A}}}\n$$\nNow, we substitute the given numerical values into this expression:\n$$\n\\text{fold-change} = \\frac{70}{120} \\cdot \\frac{8}{8}\n$$\nThe $K_m$ values are identical, so their ratio is $1$:\n$$\n\\text{fold-change} = \\frac{70}{120} = \\frac{7}{12}\n$$\nTo obtain the final answer, we convert this fraction to a decimal and round to three significant figures as requested.\n$$\n\\frac{7}{12} \\approx 0.58333...\n$$\nRounding to three significant figures, we get $0.583$. This represents a reduction in intrinsic clearance for the variant to approximately $58.3\\%$ of the wild-type value.",
            "answer": "$$\\boxed{0.583}$$"
        },
        {
            "introduction": "A change in a transporter's intrinsic function does not occur in isolation; its impact depends on the broader physiological context of the organ. This practice uses the well-stirred model to explore how a genetically-driven reduction in intrinsic uptake clearance ($CL_{\\text{int,uptake}}$) alters the overall hepatic clearance ($CL_{h}$) of a drug. This step is crucial for understanding how a molecular defect translates into a change in systemic drug exposure .",
            "id": "4572266",
            "problem": "A transporter-limited hepatic clearance scenario is considered for a highly protein-bound anionic drug whose hepatic uptake is predominantly mediated by Organic Anion Transporting Polypeptide 1B1 (OATP1B1), encoded by solute carrier organic anion transporter family member 1B1 (*SLCO1B1*). Assume linear pharmacokinetics, negligible passive diffusion relative to active uptake, negligible basolateral efflux back to blood, and that intracellular metabolism is the sole irreversible elimination pathway. The unbound drug in blood is the driving force for hepatocellular processes, and the liver behaves according to the well-stirred assumption of instantaneous mixing.\n\nStarting from first principles (mass balance and definitions of hepatic extraction and clearance under the well-stirred assumption), treat basolateral uptake and intracellular metabolism as sequential first-order processes within the hepatocyte and derive an expression for hepatic clearance $CL_{h}$ as a function of hepatic blood flow $Q_{h}$, blood fraction unbound $f_{u}$, intrinsic uptake clearance $CL_{int,uptake}$, and intrinsic metabolic clearance $CL_{int,met}$. Then, using the derived expression, compute $CL_{h}$ for the baseline scenario with $Q_{h}=90$ L/h, $f_{u}=0.05$, $CL_{int,uptake}=200$ L/h, and $CL_{int,met}=50$ L/h. Next, recompute $CL_{h}$ after reducing $CL_{int,uptake}$ to $100$ L/h to represent diminished OATP1B1 function due to an *SLCO1B1* decreased-function genotype, keeping all other parameters unchanged.\n\nExpress both computed hepatic clearances in L/h, and round your answers to four significant figures. Provide the final result as two values in the order (baseline, diminished uptake).",
            "solution": "The problem is validated as scientifically grounded, well-posed, and objective. It describes a standard pharmacokinetic scenario based on the well-stirred model of hepatic clearance, extended to include transporter-mediated uptake. The provided data are complete and consistent for solving the problem as stated.\n\nThe solution proceeds in two parts: first, the derivation of the general expression for hepatic clearance ($CL_h$) under the given assumptions, and second, the numerical computation of $CL_h$ for the two specified scenarios.\n\n**Part 1: Derivation of the Hepatic Clearance Expression**\n\nWe begin from the first principles of the well-stirred model of hepatic clearance. At steady state, the rate of drug elimination by the liver is equal to the rate of drug entry minus the rate of drug exit via the hepatic blood flow, $Q_h$.\nLet $C_{in}$ be the drug concentration in the blood entering the liver and $C_{out}$ be the drug concentration in the blood leaving the liver.\nThe rate of elimination is $Q_h (C_{in} - C_{out})$.\nHepatic clearance, $CL_h$, is defined as the rate of elimination divided by the entering drug concentration:\n$$ CL_h = \\frac{Q_h (C_{in} - C_{out})}{C_{in}} $$\nThe well-stirred model assumes that the sinusoidal blood concentration is uniform and equal to the exiting concentration, $C_{out}$. It also posits that the rate of elimination is proportional to the unbound drug concentration in this sinusoidal blood, $C_{u,out}$, and the liver's overall intrinsic clearance, $CL_{int}$. The unbound concentration is $C_{u,out} = f_u C_{out}$, where $f_u$ is the fraction unbound in blood.\nTherefore, the rate of elimination can also be expressed as:\n$$ \\text{Rate of Elimination} = CL_{int} \\cdot C_{u,out} = CL_{int} \\cdot f_u \\cdot C_{out} $$\nBy equating the two expressions for the rate of elimination, we get:\n$$ Q_h (C_{in} - C_{out}) = CL_{int} \\cdot f_u \\cdot C_{out} $$\nTo find an expression for $CL_h$, we first solve for the ratio $C_{out}/C_{in}$:\n$$ Q_h C_{in} = (Q_h + f_u CL_{int}) C_{out} $$\n$$ \\frac{C_{out}}{C_{in}} = \\frac{Q_h}{Q_h + f_u CL_{int}} $$\nThe hepatic extraction ratio, $E_h$, is $E_h = (C_{in} - C_{out})/C_{in} = 1 - C_{out}/C_{in}$.\n$$ E_h = 1 - \\frac{Q_h}{Q_h + f_u CL_{int}} = \\frac{(Q_h + f_u CL_{int}) - Q_h}{Q_h + f_u CL_{int}} = \\frac{f_u CL_{int}}{Q_h + f_u CL_{int}} $$\nHepatic clearance is $CL_h = Q_h \\cdot E_h$. Substituting the expression for $E_h$ gives the standard well-stirred model equation:\n$$ CL_h = Q_h \\frac{f_u CL_{int}}{Q_h + f_u CL_{int}} $$\nThe problem states that hepatic elimination involves two sequential first-order processes: basolateral uptake and intracellular metabolism. This means that the overall intrinsic clearance, $CL_{int}$, is a composite of the intrinsic uptake clearance, $CL_{int,uptake}$, and the intrinsic metabolic clearance, $CL_{int,met}$. For processes in series, their resistances add. Since clearance is the reciprocal of resistance, the reciprocals of the clearances add:\n$$ \\frac{1}{CL_{int}} = \\frac{1}{CL_{int,uptake}} + \\frac{1}{CL_{int,met}} $$\nSolving for $CL_{int}$:\n$$ \\frac{1}{CL_{int}} = \\frac{CL_{int,met} + CL_{int,uptake}}{CL_{int,uptake} \\cdot CL_{int,met}} $$\n$$ CL_{int} = \\frac{CL_{int,uptake} \\cdot CL_{int,met}}{CL_{int,uptake} + CL_{int,met}} $$\nSubstituting this expression for $CL_{int}$ into the well-stirred model equation yields the final derived expression for hepatic clearance as a function of all given parameters:\n$$ CL_{h} = Q_{h} \\frac{f_{u} \\left( \\frac{CL_{int,uptake} \\cdot CL_{int,met}}{CL_{int,uptake} + CL_{int,met}} \\right)}{Q_{h} + f_{u} \\left( \\frac{CL_{int,uptake} \\cdot CL_{int,met}}{CL_{int,uptake} + CL_{int,met}} \\right)} $$\n\n**Part 2: Numerical Computations**\n\n**Scenario 1: Baseline**\nThe given parameters are:\n$Q_{h} = 90$ L/h\n$f_{u} = 0.05$\n$CL_{int,uptake} = 200$ L/h\n$CL_{int,met} = 50$ L/h\n\nFirst, we compute the overall intrinsic clearance, $CL_{int}$:\n$$ CL_{int} = \\frac{200 \\times 50}{200 + 50} = \\frac{10000}{250} = 40 \\text{ L/h} $$\nNext, we compute the hepatic clearance, $CL_h$:\nThe term $f_u CL_{int}$ is $0.05 \\times 40 = 2$ L/h.\n$$ CL_{h,baseline} = 90 \\times \\frac{2}{90 + 2} = 90 \\times \\frac{2}{92} = \\frac{180}{92} \\approx 1.95652 \\text{ L/h} $$\nRounding to four significant figures, $CL_{h,baseline} = 1.957$ L/h.\n\n**Scenario 2: Diminished OATP1B1 Function**\nThe intrinsic uptake clearance is reduced, while other parameters remain unchanged:\n$Q_{h} = 90$ L/h\n$f_{u} = 0.05$\n$CL_{int,uptake} = 100$ L/h\n$CL_{int,met} = 50$ L/h\n\nFirst, we compute the new overall intrinsic clearance, $CL_{int}$:\n$$ CL_{int} = \\frac{100 \\times 50}{100 + 50} = \\frac{5000}{150} = \\frac{100}{3} \\text{ L/h} $$\nNext, we compute the new hepatic clearance, $CL_h$:\nThe term $f_u CL_{int}$ is $0.05 \\times \\frac{100}{3} = \\frac{5}{3}$ L/h.\n$$ CL_{h,diminished} = 90 \\times \\frac{\\frac{5}{3}}{90 + \\frac{5}{3}} = 90 \\times \\frac{\\frac{5}{3}}{\\frac{270+5}{3}} = 90 \\times \\frac{5}{275} = \\frac{450}{275} = \\frac{18}{11} \\approx 1.63636 \\text{ L/h} $$\nRounding to four significant figures, $CL_{h,diminished} = 1.636$ L/h.\n\nThe two computed hepatic clearances are $1.957$ L/h for the baseline scenario and $1.636$ L/h for the diminished uptake scenario.",
            "answer": "$$ \\boxed{\n\\begin{pmatrix}\n1.957 & 1.636\n\\end{pmatrix}\n} $$"
        },
        {
            "introduction": "The ultimate goal of pharmacogenomics is to use genetic information to guide clinical practice and improve patient safety. This final exercise bridges the gap between pharmacokinetic changes and clinical risk by using epidemiological data to quantify the increased risk of myopathy associated with a poor-function *SLCO1B1* genotype. You will practice calculating an odds ratio, a common measure of risk, and translating this quantitative risk into an evidence-based therapeutic recommendation .",
            "id": "4572238",
            "problem": "A clinician is initiating simvastatin therapy for a hyperlipidemic adult with a documented Solute Carrier Organic Anion Transporter Family Member 1B1 (*SLCO1B1*) genotype corresponding to the haplotype *5/*5 (poor function), compared against an otherwise matched cohort with *1/*1 (normal function). Organic Anion Transporting Polypeptide 1B1 (OATP1B1), encoded by the *SLCO1B1* gene, facilitates hepatic uptake of statins; decreased function alleles increase systemic exposure to the active acid form of simvastatin and are associated with an elevated risk of statin-associated myopathy. The planned dose is $20$ $\\mathrm{mg}$ simvastatin daily.\n\nConsider a population-based pharmacogenomic study at this dose in which, among $100{,}000$ *1/*1 individuals, $50$ experienced myopathy, and among $100{,}000$ *5/*5 individuals, $225$ experienced myopathy. Use the formal definition of the odds ratio for a binary outcome: if the probability of myopathy is $p$, then the odds are $p/(1-p)$, and the odds ratio is the ratio of odds between two groups. Compute the odds ratio of myopathy in *5/*5 versus *1/*1 at $20$ $\\mathrm{mg}$ simvastatin daily. Round your answer to three significant figures and express it as a unitless number.\n\nIn addition, based on the decreased function of OATP1B1 in the *5/*5 genotype and widely accepted clinical implementation principles (for example, those articulated by the Clinical Pharmacogenetics Implementation Consortium (CPIC)), propose an evidence-based dose reduction strategy or an alternative statin choice with a brief rationale. Your numerical answer should be only the computed odds ratio.",
            "solution": "The problem presents a valid and well-posed question grounded in established principles of clinical pharmacology and pharmacogenomics. It contains sufficient information to calculate the requested odds ratio and provide a clinical recommendation.\n\nThe problem requires the calculation of the odds ratio ($OR$) for myopathy in individuals with the *SLCO1B1* *5/*5 genotype compared to those with the *SLCO1B1* *1/*1 genotype, when treated with simvastatin $20$ $\\mathrm{mg}$ daily.\n\nFirst, we define the two groups for comparison:\nGroup 1: Individuals with the *SLCO1B1* *1/*1 (normal function) genotype.\nGroup 2: Individuals with the *SLCO1B1* *5/*5 (poor function) genotype.\n\nFrom the data provided for a population-based study:\nFor Group 1 (*1/*1):\nNumber of individuals who experienced myopathy, $C_1 = 50$.\nTotal number of individuals, $N_1 = 100,000$.\nThe number of individuals who did not experience myopathy is $NC_1 = N_1 - C_1 = 100,000 - 50 = 99,950$.\n\nFor Group 2 (*5/*5):\nNumber of individuals who experienced myopathy, $C_2 = 225$.\nTotal number of individuals, $N_2 = 100,000$.\nThe number of individuals who did not experience myopathy is $NC_2 = N_2 - C_2 = 100,000 - 225 = 99,775$.\n\nThe problem states that the odds of an event are defined as $\\frac{p}{1-p}$, where $p$ is the probability of the event. For a given group, if $C$ is the number of cases (events) and $NC$ is the number of non-cases, the probability $p$ is $\\frac{C}{C+NC}$. The odds can be calculated directly from the counts as $\\frac{C}{NC}$.\n\nThe odds of myopathy for Group 1 ($\\text{Odds}_1$) is:\n$$\n\\text{Odds}_1 = \\frac{C_1}{NC_1} = \\frac{50}{99,950}\n$$\n\nThe odds of myopathy for Group 2 ($\\text{Odds}_2$) is:\n$$\n\\text{Odds}_2 = \\frac{C_2}{NC_2} = \\frac{225}{99,775}\n$$\n\nThe odds ratio ($OR$) is the ratio of the odds in Group 2 to the odds in Group 1:\n$$\nOR = \\frac{\\text{Odds}_2}{\\text{Odds}_1} = \\frac{\\left(\\frac{225}{99,775}\\right)}{\\left(\\frac{50}{99,950}\\right)}\n$$\n\nTo calculate the value, we rearrange the expression:\n$$\nOR = \\frac{225 \\times 99,950}{99,775 \\times 50}\n$$\n\nThis corresponds to the standard cross-product ratio from a $2 \\times 2$ contingency table, where the cells are $a$ (cases in exposed group), $b$ (non-cases in exposed group), $c$ (cases in unexposed group), and $d$ (non-cases in unexposed group). Here, Group 2 is the \"exposed\" group (to the genetic variant) and Group 1 is the \"unexposed\" group. Thus, $a=C_2=225$, $b=NC_2=99,775$, $c=C_1=50$, and $d=NC_1=99,950$. The formula is $OR = \\frac{ad}{bc}$.\n\nPerforming the calculation:\n$$\nOR = \\frac{22,488,750}{4,988,750} \\approx 4.508018\n$$\n\nThe problem requires rounding the answer to three significant figures.\n$$\nOR \\approx 4.51\n$$\n\nIn addition to the calculation, the problem asks for an evidence-based recommendation for the patient with the *5/*5 genotype.\nThe *SLCO1B1* gene encodes the hepatic uptake transporter OATP1B1. The *5/*5 genotype results in a poor-function phenotype of this transporter. Simvastatin acid is a substrate of OATP1B1. Decreased transporter function leads to reduced hepatic clearance and consequently increased systemic plasma concentrations of simvastatin acid. This increased systemic exposure is directly linked to an elevated risk of statin-associated myopathy, an observation confirmed by our calculated odds ratio of approximately $4.51$.\n\nBased on widely accepted clinical guidelines, such as those published by the Clinical Pharmacogenetics Implementation Consortium (CPIC), this patient is at a significantly increased risk for myopathy at the planned $20$ $\\mathrm{mg}$ daily dose of simvastatin. The evidence-based recommendation is not simply a dose reduction but a change of therapy. The CPIC guidelines for simvastatin and *SLCO1B1* poor function phenotype recommend using an alternative statin. Statins such as pravastatin and rosuvastatin are less dependent on OATP1B1 for their hepatic uptake compared to simvastatin. Fluvastatin is also a recommended alternative. Therefore, the most appropriate clinical action is to discontinue the plan for simvastatin and instead prescribe an alternative like pravastatin or rosuvastatin at an appropriate equipotent dose. This strategy mitigates the risk of myopathy by choosing a drug whose pharmacokinetics are not substantially altered by the patient's genetic variant. While lowering the simvastatin dose (e.g., to $10$ $\\mathrm{mg}$) is a theoretical option, it may not be sufficient to eliminate the excess risk and could compromise the therapeutic goal of lipid reduction. Thus, switching agents is the preferred, evidence-based strategy.",
            "answer": "$$\n\\boxed{4.51}\n$$"
        }
    ]
}